These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 39018723)

  • 1. Clinical Outcomes and Risk Stratification in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With New-Generation Androgen Receptor Signaling Inhibitors.
    Suzuki K; Shiraishi Y; Furukawa J; Okamura Y; Bando Y; Hara T; Okada K; Terakawa T; Hyodo Y; Chiba K; Teishima J; Nakano Y; Miyake H
    Clin Genitourin Cancer; 2024 Oct; 22(5):102140. PubMed ID: 39018723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic outcomes in Japanese patients with metastatic castration-sensitive prostate cancer: Comparative assessments between conventional androgen deprivation therapy (ADT) and ADT with novel androgen receptor signal inhibitor.
    Watanabe H; Nakane K; Takahara K; Naiki T; Yasui T; Shiroki R; Koie T; Miyake H
    Int J Urol; 2024 Sep; 31(9):986-993. PubMed ID: 38764245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a study in the real world.
    Lu Y; Jiang J; Yang G; Ding H; Zheng Q; Ji L; Wang Y; Dong Z; Zhai Z; Tian J; Zhang Y; Wang J; Yang L; Wang Z
    Front Oncol; 2024; 14():1324181. PubMed ID: 38699643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration-resistant prostate cancer patients.
    Tanegashima T; Shiota M; Tsukahara S; Mutaguch J; Goto S; Kobayashi S; Matsumoto T; Eto M
    Prostate; 2024 Oct; 84(14):1329-1335. PubMed ID: 38988005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: the role of combination treatment therapy.
    Afferi L; Longoni M; Moschini M; Gandaglia G; Morgans AK; Cathomas R; Mattei A; Breda A; Scarpa RM; Papalia R; de Nunzio C; Esperto F
    Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):173-182. PubMed ID: 37055663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.
    Qu F; Xie W; Nakabayashi M; Zhang H; Jeong SH; Wang X; Komura K; Sweeney CJ; Sartor O; Lee GM; Kantoff PW
    Clin Cancer Res; 2017 Feb; 23(3):726-734. PubMed ID: 27489290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in Prostate Cancer Treatment and Drug Discovery.
    Nevedomskaya E; Baumgart SJ; Haendler B
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29734647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial.
    Vaishampayan UN; Heilbrun LK; Monk P; Tejwani S; Sonpavde G; Hwang C; Smith D; Jasti P; Dobson K; Dickow B; Heath EI; Semaan L; Cher ML; Fontana JA; Chinni S
    JAMA Netw Open; 2021 Jan; 4(1):e2034633. PubMed ID: 33496795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis.
    Gomez-Veiga F; Szmulewitz RZ; Holzbeierlein J; Azad AA; Iguchi T; Villers A; Alcaraz A; Alekseev B; Shore ND; Rosbrook B; Zohren F; Ma J; Haas GP; Stenzl A; Armstrong AJ
    Eur Urol Oncol; 2024 Aug; 7(4):860-869. PubMed ID: 38072761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis.
    Chen X; Wang Q; Pan Y; Wang S; Li Y; Zhang H; Xu M; Zhou H; Liu X
    Front Endocrinol (Lausanne); 2023; 14():1134719. PubMed ID: 36967752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
    Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
    Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
    Altavilla A; Casadei C; Lolli C; Menna C; Ravaglia G; Gurioli G; Farolfi A; Brighi N; Conteduca V; Burgio SL; Schepisi G; Rossi L; Gargiulo S; Lisotti I; De Giorgi U
    Expert Opin Pharmacother; 2020 Dec; 21(17):2091-2099. PubMed ID: 32783772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors: A Systematic Review and Meta-analysis.
    Myint ZW; Momo HD; Otto DE; Yan D; Wang P; Kolesar JM
    JAMA Netw Open; 2020 Nov; 3(11):e2025826. PubMed ID: 33201234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis.
    Yamada Y; Matsubara N; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S
    BMC Res Notes; 2016 Oct; 9(1):471. PubMed ID: 27756383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer.
    Ueda T; Shiraishi T; Ito S; Ohashi M; Matsugasumi T; Yamada Y; Fujihara A; Hongo F; Okihara K; Ukimura O
    Sci Rep; 2021 May; 11(1):10094. PubMed ID: 33980956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
    Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
    Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Mori K; Mostafaei H; Pradere B; Motlagh RS; Quhal F; Laukhtina E; Schuettfort VM; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF
    Int J Clin Oncol; 2020 Nov; 25(11):1892-1900. PubMed ID: 32924096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors.
    Gebrael G; Sayegh N; Thomas VM; Chigarira B; Tripathi N; Jo YJ; Li H; Sahu KK; Srivastava A; McFarland T; Maughan BL; Swami U; Agarwal N
    Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):279-282. PubMed ID: 37460732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.
    George DJ; Morgans AK; Constantinovici N; Khan N; Khan J; Chen G; Hlebec V; Shore ND
    JAMA Netw Open; 2024 Aug; 7(8):e2429783. PubMed ID: 39190308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Warning against second-generation antiandrogen for metastatic castration sensitive prostate cancer.
    Inoue T; Sasaki T; Kato M; Masui S; Nishikawa K
    BJU Int; 2021 Nov; 128(5):550. PubMed ID: 34333840
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.